Cambridge Scientific, Inc.'s Polymer Based DONTEX Bone Graft Substitutes Correlate with Healing Bone and Potentially Maintain Bony Contour.

Business Editors & Health/Medical Writers

BIOWIRE2K

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 30, 2003

Cambridge Scientific, Inc. will present preclinical results demonstrating its biopolymer-based DONTEX(TM) Bone Graft Substitute provides mechanical properties similar to bone at the Orthopedic Research Society's annual meeting in New Orleans, LA, February 2-3, 2003.

The CSI presentation entitled "MECHANICAL QUALIFICATION OF A SYNTHETIC, RESORBABLE BONE REPAIR SCAFFOLD," discusses the potential for CSI's porous, bioabsorbable, polymer-based bone graft substitute to augment the use of cancellous autograft or replace allograft in bone repair applications. This product yields a tissue engineered scaffold that possesses mechanical properties similar to cancellous bone and supports native bony cell ingrowth and subsequent osteointegration.

Healing bone recovers half of its mechanical properties within three weeks; DONTEX(TM) retains 50% of its mechanical strength at three weeks and absorbs at a rate commensurate with bony healing. Thus, timeframes for bioabsorption of DONTEX(TM) and defect healing are compatible. Due to timing and mechanical attributes, DONTEX(TM) can be used not only in orthopedic applications where stability is necessary, but also in indications where cosmetic aspects are important. Dr. Robert S. Langer, Professor of Chemical and Biomedical Engineering at the Massachusetts Institute of Technology and a Director of CSI, commented that "DONTEX(TM) has great potential for use in a wide range of applications, from periodontics and craniomaxillofacial surgery to trauma and spinal fusion." Physicians familiar with the material are excited about the ease of handling and the product's formulation as an injectable product or moldable putty.

Cambridge Scientific, Inc. is a private, biomedical research and technology firm located in Cambridge, Massachusetts, dedicated to commercializing biopolymer-based medical technologies. In July 2002, CSI received 510(k) clearance for its WISORB(TM) Malleolar Screw, a bioabsorbable fixation device. CSI is also actively developing the WISORB(TM) Spinal Fusion System, a bioabsorbable spinal fusion device, to complement its orthopedic product portfolio. For more information visit: www.cambridgescientificinc.com

This news release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements, including statements about product development status and clinical trials, represent the company's judgment as of the time of this release. The company disclaims any intent or obligation to update these forward-looking statements.